Table 1 Patient characteristics
Total | 39 |
|---|---|
Sex, N (%) | |
 Male | 22 (56%) |
 Female | 17 (44%) |
Age, median (range) | 60 (31-78) years |
Disease, N (%) | |
 Acute myeloid leukemia | 33 (85%) |
 Other high-grade myeloid malignancy | 6 (15%) |
Disease type, N (%) | |
 De novo | 32 (82%) |
 Treatment-related | 4 (10%) |
 Secondary | 3 (8%) |
Disease phase, N (%) | |
 New diagnosis | 33 (85%) |
 Relapsed/Refractory | 6 (15%) |
Chemotherapy regimen, N (%) | |
 CLAG-M + /− GO +/− midostaurin | 35 (90%) |
 FLAG-Ida + venetoclax | 3 (7%) |
 Liposomal daunorubicin and cytarabine (Vyxeos) | 1 (3%) |
First hospitalization length, median (range) | 12 (5-42) days |
Fever/Infection episodes by day 30, N (%)a | |
 Median (range) | 2 (0-6) |
 Number of episodes | 10 (28%) |
 1 | 14 (36%) |
 2 | 9 (23%) |
 3 | 2 (5%) |
 4 | 2 (5%) |
 6 | 1 (3%) |
Fever/Infection type, N (%)b,c | |
 Neutropenic fever without microbiological documentation | 37 (41%) |
 Bloodstream infection | 18 (20%) |
 Skin and soft tissue infection | 9 (10%) |
 Lower respiratory tract infection | 9 (10%) |
 Gastrointestinal infection | 8 (9%) |
 Urogenital infection | 3 (3%) |
 Oral cavity infection | 3 (3%) |
 Upper respiratory tract infection | 2 (2%) |
Readmission by day 30 of chemotherapy, N (%)d | 21 (54%) |
Death by day 30 of chemotherapy, N (%) | 2 (5%) |
 Infection | 1 |
 Stress cardiomyopathy | 1 |
